

10/581269

AP20 Rec'd PCT/PTO 01 JUN 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Stefan ARNOLD et al.

Title: ERYTHROPOIETIN SOLUTION FORMULATION

Appl. No.: Not Assigned

Filing Date: June 1, 2006

Examiner: Not Assigned

Art Unit: Not Assigned

Atty Docket No: LNK-009

MAIL STOP AMENDMENT

Honorable Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached form PTO-1449. It is respectfully requested that the documents be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. Accordingly, no certification or fee is required.

Copies of the foreign patent and non-patent literature references are enclosed herewith. However, in accordance with the revised procedures under 37 CFR 1.98(a)(2)(i), copies of the cited U.S. patent references have not been provided.

JAP20 Rec'd PCT/PTO 01 JUN 2006

In accordance with 37 C.F.R. §§ 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search had been made or that information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item, and Applicant reserves the right to prove that the date of publication is in fact different.

The Commissioner is authorized to charge any deficiency in any fees pursuant to 37 CFR § 1.17 associated with this communication and to credit any excess payment to Deposit Account No. 50-2101.

Respectfully submitted,

Date: 06/01/06

By: Chalin A. Smith

SMITH PATENT CONSULTING, LLC
P.O. Box 2726
Alexandria, VA 22301

Name: Chalin A. Smith
Title: Attorney for Applicant
Registration No. 41,569

Tel: 703-549-7691
Fax: 703-549-7692

CUSTOMER NUMBER 31,496

SHEET 1 OF 1

INFORMATION DISCLOSURE CITATION IN AN APPLICATION (PTO-1449)		ATTY. DOCKET NO. LNK-009	SERIAL NO. 201591269 <small>(Not Assigned (National Phase of PCT/EP04/013619)</small>				
		APPLICANT Stefan ARNOLD et al.					
		NATIONAL PHASE FILING DATE June 1, 2006	GROUP Not Assigned				
U.S. PATENT DOCUMENTS							
EXAMINER'S INITIALS	PATENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE	
	4,806,524	02-1989	Kawaguchi et al.	514	8		
	4,992,419	02-1991	Woog et al.	514	8		
	2003/0148938 A1	08-2003	Sharma et al.	514	12		
EXAMINER'S INITIALS	PATENT NO.	DATE	COUNTRY/APPLICANT	CLASS	SUBCLASS	Translation Yes No	
	EP 0 456 153 A1	05-1991	EPO (BEHRINGWERKE)	A61K	37/02		X
	EP 0 909 564 A1	04-1999	EPO (CHUGAI)	A61K	38/22		
	DE 101 61 577 A1	07-2003	DE (Scil Proteins GmbH)	C07K	14/00		X
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
	International Search Report and Written Opinion of the International Searching Authority issued in PCT/EP04/013619 (05/31/2005)						
	International Preliminary Report on Patentability issued in PCT/EP04/013619 (01/27/2006)						

EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.